Aldeyra Therapeutics, Inc. ALDX

Updated: 10 Aug 2026

NASDAQ | Biotech | Biotechnology / Drug development

No signal published yet

We already track Aldeyra Therapeutics and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.

Follow Aldeyra Therapeutics free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Free
No email, no account, no signup.
Exchange
NASDAQ
Type
Biotech
Sector
Biotechnology / Drug development
We're already tracking Aldeyra Therapeutics, Inc. — here are the latest events we've registered

Recent News

  • On August 6, 2026, Aldeyra reported its Q2 2026 financial results with a net loss of $5.45 million. The company stated that its cash position is expected to fund operations into the second half of 2028 and noted that its credit facility was fully repaid in April 2026.

What Firelda Watch includes for Aldeyra Therapeutics, Inc.

Add the company to your watchlist and get all of this automatically.

  • Free: 3 companies on your watchlist
  • Change history and monitoring for every company you follow
  • Sunday weekly brief — a short weekly roundup
  • Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Aldeyra Therapeutics, Inc. will be delivered in the same format.

Want to follow Aldeyra Therapeutics, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.

Follow Aldeyra Therapeutics free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Aldeyra Therapeutics, Inc. ALDX
Aldeyra Therapeutics — follow and we'll monitor it
Follow Aldeyra Therapeutics free Follow free
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.